{"entity":{"id":"finite-tissue-budget","kind":"term","name":"Finite tissue and specimen allocation","aka":["finite tissue budget","tissue allocation for testing"],"tldr":"Sections, extractions and destructive tests consume stored tissue. Planning several tests requires knowing what material remains and which uses it must support.","summary":"NCI biospecimen guidance places pathology oversight of tissue release alongside the need to protect complete medical evaluation. It also treats divided and extracted material as traceable derivative samples. A thoracic small-specimen guideline addresses triage and handling for multiple ancillary studies in its own clinical scope. The general resource issue is finite material, not a universal order of tests: remaining tissue and assay requirements need to be established for the actual specimen.","asOf":"2026-11-10","links":[{"label":"NCI Best Practices for Biospecimen Resources, fourth edition (2026)","url":"https://dctd.cancer.gov/data-tools-biospecimens/biospecimens-biobanks/resources/best-practices/biospecimen-resources/intro"},{"label":"Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology.","url":"https://doi.org/10.5858/arpa.2020-0119-cp"},{"label":"Biospecimen & Biorepository Basics - NCI","url":"https://dctd.cancer.gov/data-tools-biospecimens/biospecimens-biobanks/basics"},{"label":"CAP practical breast grossing guide excerpt","url":"https://documents-cloud.cap.org/pdf/Grossing_Sample.pdf"},{"label":"NCI Biospecimen Evidence-Based Practices: snap-freezing of post-surgical tissue","url":"https://dctd.cancer.gov/data-tools-biospecimens/snap-freeze-bebp.pdf"}],"tags":[],"related":["specimen-provenance","tissue-preparation-assay-fit","preanalytics-sample-stabilisation","biopsy"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Cutting sections moves material from the block onto slides; extraction consumes a portion and loses its original architecture. Stored images and datasets can be copied and reanalysed but cannot refill the archive. A newly collected biopsy is another procedure and time point, and a growing culture is a changed system rather than replenishment of the original specimen.","An aliquot is an allocated portion. Retain site, date, treatment context, preservation, region, quantity, prior uses, remaining material, permissions and custody. A block list or ten remaining slides does not prove that relevant malignant cells remain. Returning a block does not replace extracted tissue.","Fictional small block: one proposed extraction remains possible after diagnostic needs are protected, while two teams request overlapping RNA tests. Compare questions, validated inputs, existing-data reuse, permissions and expected material use with pathology before allocation. No universal section count, percentage budget or clinical priority follows from this exercise.","Specimen allocation starts by identifying the available portions, assessing their suitability, estimating method-specific use and recording consumption. Blocks, slides, frozen pieces and cell aliquots are finite inputs; their counts alone do not establish adequacy. Record remaining portions with section thickness, area or analyte amounts and the relevant context. Receiving-laboratory requirements and diagnostic priorities apply, rather than a universal test budget. Outdated inventories, unrecognised exhaustion, unsuitable regions and duplicated destructive work can waste material. Specimen governance supports reliable testing but is not itself a clinical biomarker and does not establish whether a test changes care or another procedure is appropriate."],"category":"Diagnostics & imaging"},"route":"/terms/finite-tissue-budget/","neighbours":{"term":[{"id":"biopsy","kind":"term","name":"Biopsy","route":"/terms/biopsy/"},{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"immunopeptidomics","kind":"term","name":"Immunopeptidomics","route":"/terms/immunopeptidomics/"},{"id":"specimen-provenance","kind":"term","name":"Specimen provenance and derivative tracking","route":"/terms/specimen-provenance/"},{"id":"tissue-preparation-assay-fit","kind":"term","name":"Tissue preparation and assay suitability","route":"/terms/tissue-preparation-assay-fit/"}],"technology":[{"id":"preanalytics-sample-stabilisation","kind":"technology","name":"Pre-analytics: blood-collection tubes and tissue fixation","route":"/technologies/preanalytics-sample-stabilisation/"}]}}